Aratana Therapeutics Inc  

(Public, NASDAQ:PETX)   Watch this stock  
Find more results for Wendy L. Yarno
3.29
-0.30 (-8.36%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.25 - 3.56
52 week 2.65 - 20.63
Open 3.56
Vol / Avg. 750,432.00/623,293.00
Mkt cap 125.67M
P/E     -
Div/yield     -
EPS -2.37
Shares 35.01M
Beta     -
Inst. own 102%
Mar 15, 2016
Aratana Therapeutics Inc at Barclays Global Healthcare Conference Add to calendar
Mar 10, 2016
Q4 2015 Aratana Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 16, 2015
Aratana Therapeutics Inc at Bank of America Merrill Lynch Animal Health Summit
Dec 1, 2015
Aratana Therapeutics Inc at Piper Jaffray Healthcare Conference
Nov 17, 2015
Aratana Therapeutics Inc at Stifel Healthcare Conference
Nov 12, 2015
Aratana Therapeutics Inc 2015 Investor Day
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -23773.80% -5060.76%
Operating margin -24020.52% -5424.90%
EBITD margin - -5158.54%
Return on average assets -136.34% -24.24%
Return on average equity -157.07% -29.27%
Employees 55 -
CDP Score - -

Address

11400 Tomahawk Creek Pkwy Ste 340
LEAWOOD, KS 66211-2730
United States - Map
+1-913-3531000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both. The Company's target indications include pain and inflammation associated with osteoarthritis, inappetence, post-operative pain, lymphoma, osteosarcoma, atopic dermatitis, ocular herpes and feline immunodeficiency virus. The Company's most advanced products from a development and commercialization perspective, AT-004 and AT-005, are monoclonal antibodies (MAbs) for treating lymphoma in dogs.

Officers and directors

Wendy L. Yarno Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Steven St. Peter M.D President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Craig A. Tooman Chief Financial Officer, Treasurer
Age: 49
Bio & Compensation  - Reuters
Linda Rhodes Ph.D. Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
Ernst Heinen Ph.D. Chief Development Officer
Age: 52
Bio & Compensation  - Reuters
Julia A. Stephanus Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 57
Bio & Compensation  - Reuters
David L. Brinkley Independent Director
Age: 57
Bio & Compensation  - Reuters
Robert Benthall Gerber Jr. Independent Director
Age: 52
Bio & Compensation  - Reuters
Irvine O. Hockaday Esq. Independent Director
Age: 79
Bio & Compensation  - Reuters